Electrochemical determination of chloramphenicol and metronidazole by using a glassy carbon electrode modified with iron, nitrogen co-doped nanoporous carbon derived from a metal-organic framework (type Fe/ZIF-8).

In this study, an iron-doped metal-organic framework (MOF) Fe/ZIF-8 was synthesized from ZIF-8 at room temperature. Direct carbonization of Fe/ZIF-8 under a nitrogen atmosphere produced nanoporous nitrogen doped carbon nanoparticles decorated with Fe component (Fe/NC). The Fe/NC exhibited a large surface area (1221.185 m2 g-1) and narrow pore-size distribution (3-5 nm). The nanoporous Fe/NC components along with Nafion were used to modify a glassy carbon electrode for the electrochemical determination of chloramphenicol and metronidazole via linear sweep voltammetry. Under optimal conditions, the reduction peak currents (observed at -0.237 V and -0.071 V vs. Ag/AgCl) of these analytes increased linearly with increasing chloramphenicol and metronidazole concentrations in the range of 0.1-100 µM and 0.5-30 µM, with the detection limits estimated to be 31 nM and 165 nM, respectively. This result was attributed to the large surface area, porous structure, high nitrogen content, and as well as the electrocatalytic effect of Fe atoms embeded in the carbon support. The proposed sensor was used for chloramphenicol and metronidazole analysis in samples, providing satisfactory results.

Synthesis, characterization and catalytic performance of nanostructured dysprosium molybdate catalyst for selective biomolecule detection in biological and pharmaceutical samples.

The current study reports a new, simple and fast method using a flake-like dysprosium molybdate (Dy2MoO6; FL-DyM) nanostructured material to detect the antibiotic drug metronidazole (METZ). This nanocomposite material was employed on the surface of a glassy carbon electrode (GCE) to develop the electrode (FL-DyM/GCE). Further, the synthesized FL-DyM was systematically characterized by powder X-ray diffraction (XRD), Raman spectroscopy, scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy-dispersive X-ray diffraction (EDS), elemental mapping, X-ray photoelectron spectroscopy (XPS), and Brunauer-Emmett-Teller (BET) analyses. Cyclic (CV) and differential pulse voltammetry (DPV) techniques were used to study the electrochemical properties. The FL-DyM/GCE-based sensor demonstrated excellent selectivity and sensitivity for the detection of the drug METZ, which could be attributed to the strong affinity of FL-DyM towards the -NO2 group in METZ, and the good electrocatalytic activity and conductivity of FL-DyM. The fabrication and optimization of the working electrode were accomplished with CV and DPV obtained by scan rate and pH studies. Compared to the bare GCE and other rare-earth metal molybdates, the FL-DyM/GCE sensor displayed a superior electrocatalytic activity response for METZ detection. The sensor demonstrated a good linear relationship over the concentration range of 0.01-2363 µM. The quantification and detection limits were found to be 0.010 µM and 0.0030 µM, respectively. The FL-DyM/GCE sensor displayed excellent selectivity, repeatability, reproducibility, and stability for the detection of METZ in human urine and commercial METZ tablet samples, which validates the new technique for efficient drug sensing in practical applications.

CuCo2O4/N-Doped CNTs loaded with molecularly imprinted polymer for electrochemical sensor: Preparation, characterization and detection of metronidazole.

CuCo2O4 nanoparticles modified with nitrogen doped carbon nanotubes (CuCo2O4/N-CNTs) have high specific surface area and good electrical conductivity. Herein, a novel electrochemical sensor based on CuCo2O4/N-CNTs loaded molecularly imprinted polymer (MIP) modified glassy carbon electrode (GCE) is proposed for rapid and ultrasensitive detection of metronidazole (MNZ). The composite of CuCo2O4/N-CNTs with MIP significantly enhances the electrical signal. The electrochemical polymerization was performed with MNZ as template and aniline as functional monomer by cyclic voltammetry (CV), and differential pulse voltammetry (DPV) was used to detect MNZ. Factors that affect sensor response were optimized. Under the optimal experimental conditions, the DPV current response shows two linearity ranges for MNZ in the range of 0.005-0.1 µM and 0.1-100 µM with very low limit of detection (LOD) of 0.48 nM (S/N = 3). This electrochemical sensing system has high sensitivity, selectivity, excellent reproducibility, repeatability and stability. The recovery (95.9%-100.9%) and reasonable relative standard deviation (RSD) (3.2%-4.8%) for determination of real samples indicate the practicality of the sensing system. This sensing system has high potential for rapid determination of MNZ in samples such as metronidazole tablets, human serum and urine.

In-situ insertion of multi-walled carbon nanotubes in the Fe3O4/N/C composite derived from iron-based metal-organic frameworks as a catalyst for effective sensing acetaminophen and metronidazole.

In this paper, a novel Fe3O4/N/C@MWCNTs composite derived from iron-based metal-organic frameworks (H2N-Fe-MIL-88B) with multi-walled carbon nanotubes (MWCNTs) was prepared successfully through a simple calcination process. X-ray diffraction, scanning electron microscopy, transmission electron microscopy, Fourier-transform infrared spectroscopy, X-ray photoelectron spectroscopy and electrochemical measurements were employed to comprehensive characterize the composites. Compare with the physical mixture, in-situ insertion of MWCNTs in the Fe3O4/N/C formed Fe3O4/N/C@MWCNTs composite has the higher conductivity, larger BET surface area and more satisfying electrocatalytic properties. Meanwhile, this composite with the reasonable combinations exhibits remarkable electrocatalytic activities for acetaminophen (AP) and metronidazole (MNZ) due to the synergistic interaction between the components. Thus, the Fe3O4/N/C@MWCNTs-2-600-based electrochemical sensor was established to effectively detect these two medicine molecules, respectively. In the optimized test conditions, the proposed sensor exhibits a wide linear response (0.5-5.0 µM and 5.0-1355.0 µM) for AP and the limit of detection (LOD) was achieved to be 0.14 µM (S/N = 3). Meanwhile, this sensor also shows two linear relationships with the concentration of MNZ in the range of 1.0 µM to 10.0 µM and 10.0 µM to 725.0 µM with the LOD of 0.19 µM (S/N = 3). Moreover, the satisfactory results were also acquired when the proposed sensor was used for the determination of AP and MNZ in the human serum and urine, demonstrating great promising of this electrochemical sensor for clinical applications.

Green synthesis of graphitic carbon nitride nanosheet (g-C3N4) and using it as a label-free fluorosensor for detection of metronidazole via quenching of the fluorescence.

In this research, g-C3N4nanosheets were facilely fabricated by thermal polymerization and then exfoliated into ultrathin nanosheets through ultrasonication in water media. Low-cost C-N nanosheets prepared by melamine possessed a highly π-conjugated structure and fluorescence property. In the present study, the g-C3N4nanosheet was used as a switch-off fluorescence sensor for rapid and sensitive sensing of metronidazole in biological fluids. These nanosheets were characterized by X-ray diffraction (XRD), transmission electron microscopy (TEM), and Fourier transform infrared (FTIR) spectroscopy. The fluorescence of the solution of the g-C3N4nanosheets was quenched effectively by metronidazole through two mechanisms: fluorescence resonance energy transfer and the formation of a donor-acceptor charge-transfer complex between π-electron rich donors. Under optimal conditions, the detection linear range for metronidazole was found to be from 0.01 to 0.10µgml-1, with a limit of detection (LOD) of 0.008µgml-1 which can cover standard range of metronidazole in real samples. Moreover, the proposed method has offered a green, rapid, and sensitive probe for quantitative determination of metronidazole in drug and biological fluids.

Carbon paste electrode modified with duplex molecularly imprinted polymer hybrid film for metronidazole detection.

A novel electrochemical sensor based on duplex molecularly imprinted polymer (DMIP) hybrid film modified carbon paste electrode (CPE) has been developed for highly sensitive and selective determination of metronidazole (MNZ). A conductive poly(anilinomethyltriethoxysilane) film is firstly electrodeposited on the surface of a CPE, and then a molecularly imprinted polysiloxane (MIPS) membrane is covalently covered on the film via sol-gel process. The as-constructed DMIP hybrid film, combining the advantages of MIPS and conducting MIP, can make feasible the direct and efficient signal transformation between the target analyte and the transducer, as well as enhance the imprinting recognition capability, mass transfer efficiency and the detection sensitivity. Under optimized conditions, the reduction peak currents of MNZ are linear to MNZ concentrations in the range from 4.0×10(-7) to 2.0×10(-4) molL(-1) with a detection limit of 9.1×10(-8)molL(-1). The RSD values vary from 2.9% to 4.7% for intra-day and from 3.4% to 4.2% for inter-day precision. The DMIP-based sensor has been successfully applied for the determination of MNZ in biological and pharmaceutical samples. The accuracy and reliability of the method is further confirmed by high performance liquid chromatography.

Enhanced amperometric detection of metronidazole in drug formulations and urine samples based on chitosan protected tetrasulfonated copper phthalocyanine thin-film modified glassy carbon electrode.

An enhanced electrocatalytic reduction of metronidazole antibiotic drug molecule using chitosan protected tetrasulfonated copper phthalocyanine (Chit/CuTsPc) thin-film modified glassy carbon electrode (GCE) has been developed. An irreversible reduction occurs at -0.47V (vs. Ag/AgCl) using Chit/CuTsPc modified GCE. A maximum peak current value is obtained at pH1 and the electrochemical reduction reaction is a diffusion controlled one. The detection limit is found to be 0.41nM from differential pulse voltammetry (DPV) method. This present investigation method is adopted for electrochemical detection of metronidazole in drug formulation and urine samples by using DPV method.

Boron doped diamond sensor for sensitive determination of metronidazole: Mechanistic and analytical study by cyclic voltammetry and square wave voltammetry.

The performance of boron-doped diamond (BDD) electrode for the detection of metronidazole (MTZ) as the most important drug of the group of 5-nitroimidazole was proven using cyclic voltammetry (CV) and square wave voltammetry (SWV) techniques. A comparison study between BDD, glassy carbon and silver electrodes on the electrochemical response was carried out. The process is pH-dependent. In neutral and alkaline media, one irreversible reduction peak related to the hydroxylamine derivative formation was registered, involving a total of four electrons. In acidic medium, a prepeak appears probably related to the adsorption affinity of hydroxylamine at the electrode surface. The BDD electrode showed higher sensitivity and reproducibility analytical response, compared with the other electrodes. The higher reduction peak current was registered at pH11. Under optimal conditions, a linear analytical curve was obtained for the MTZ concentration in the range of 0.2-4.2µmolL(-1), with a detection limit of 0.065µmolL(-1).

The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans.

Patients are usually exposed to multiple drugs, and metabolite profiling of each drug in complex biological matrices is a big challenge. This study presented a new application of an improved high resolution mass spectrometry (HRMS)-based data-mining tools in tandem to fast and comprehensive metabolite identification of combination drugs in human. The model drug combination was metronidazole-pantoprazole-clarithromycin (MET-PAN-CLAR), which is widely used in clinic to treat ulcers caused by Helicobacter pylori. First, mass defect filter (MDF), as a targeted data processing tool, was able to recover all relevant metabolites of MET-PAN-CLAR in human plasma and urine from the full-scan MS dataset when appropriate MDF templates for each drug were defined. Second, the accurate mass-based background subtraction (BS), as an untargeted data-mining tool, worked effectively except for several trace metabolites, which were buried in the remaining background signals. Third, an integrated strategy, i.e., untargeted BS followed by improved MDF, was effective for metabolite identification of MET-PAN-CLAR. Most metabolites except for trace ones were found in the first step of BS-processed datasets, and the results led to the setup of appropriate metabolite MDF template for the subsequent MDF data processing. Trace metabolites were further recovered by MDF, which used both common MDF templates and the novel metabolite-based MDF templates. As a result, a total of 44 metabolites or related components were found for MET-PAN-CLAR in human plasma and urine using the integrated strategy. New metabolic pathways such as N-glucuronidation of PAN and dehydrogenation of CLAR were found. This study demonstrated that the combination of accurate mass-based multiple data-mining techniques in tandem, i.e., untargeted background subtraction followed by targeted mass defect filtering, can be a valuable tool for rapid metabolite profiling of combination drugs in vivo.

Kinetic spectrophotometric H-point standard addition method for the simultaneous determination of diloxanide furoate and metronidazole in binary mixtures and biological fluids.

Simple, reliable, and sensitive kinetic spectrophotometric method has been developed for the simultaneous determination of diloxanide furoate and metronidazole using H-point standard addition method (HPSAM). The method is based on the oxidation rate difference of diloxanide and metronidazole by potassium permanganate in basic medium. A green color has been developed and measured at 610 nm. Different experimental parameters were carefully optimized. The limiting logarithmic and the initial-rate methods were adopted for the construction of the calibration curve of each individual reaction with potassium permanganate. Under the optimum conditions, Beer's law was obeyed in the range of 1.0-20.0 and 5.0-25.0 µg ml(-1) for diloxanide furoate and metronidazole, respectively. The detection limits were 0.22 µg ml(-1) for diloxanide furoate and 0.83 µg ml(-1) for metronidazole. Correlation coefficients of the regression equations were greater than 0.9970 in all cases. The precision of the method was satisfactory; the maximum value of relative standard deviation did not exceed 1.06% (n=5). The accuracy, expressed as recovery was between 99.4% and 101.4% with relative error of 0.12 and 0.14 for diloxanide furoate and metronidazole, respectively. The proposed method was successfully applied for the simultaneous determination of both drugs in pharmaceutical dosage forms and human urine samples and compared with alternative HPLC method.

Simultaneous determination of the combined drugs of ceftriaxone sodium, metronidazole, and levofloxacin in human urine by high-performance liquid chromatography.

AIM: To develop a new high-performance liquid chromatography (HPLC) method for simultaneous determination of the combined drugs (ceftriaxone sodium, metronidazole, and levofloxacin) in human urine. METHODS: Ceftriaxone sodium, metronidazole, and levofloxacin were separated on a Kromasil 100-5 C18 (250 mm × 4.6 mm, 5 µm, AKZO NOBEL, Bohus, Sweden) analytical column, using the mobile phase consisted of 1.5 mM KH(2) PO(4) (pH 4.5) with 0.0125% triethylamine-methnol (70:30, v/v). Ceftriaxone sodium, metronidazole, and levofloxacin were detected by a photodiode-array detector at 247, 320, 292 nm, respectively. RESULTS: Under optimal conditions, the effective separation of ceftriaxone sodium, metronidazole, and levofloxacin was achieved. A good linearity with the correlation coefficients more than 0.999 was demonstrated. The detection limits of ceftriaxone sodium, metronidazole, and levofloxacin were 0.05, 0.01, and 0.25 µg/ml, respectively, and the average recoveries in human urine were in the range from 97.73 to 100.7% with the average relative standard deviation (RSD) in the range of 2.5% and 3.0%. CONCLUSION: The proposed method was sensitive, accurate, and rapid. This work may provide a reference for clinical rational drug use and methodology for the pharmacokinetics study of the combined drugs.

Method validation and determinations of levofloxacin, metronidazole and sulfamethoxazole in an aqueous pharmaceutical, urine and blood plasma samples using quantitative nuclear magnetic resonance spectrometry.

Selective, rapid and accurate quantitative proton nuclear magnetic resonance (qHNMR) method for the determination of levofloxacin, metronidazole benzoate and sulfamethoxazole in aqueous solutions was developed and validated. The method was successfully applied to the determinations of the drugs and their admixtures in pharmaceutical, urine and plasma samples. Maleic acid and sodium malate were used as internal standards. Effect of temperature on spectral measurements was evaluated. Linear dynamic ranges of 0.50-68.00, 0.13-11.30 and 0.24-21.00 mg per 0.60 mL solution were obtained for levofloxacin, metronidazole benzoate and sulfamethoxazole, respectively. Average recovery % in the range of 96.00-104.20 ± (0.17-2.91) was obtained for drugs in pure, pharmaceutical, plasma and urine samples. Inter and intra-day analyses gave average recoveries % in the ranges 96.10-98.40 ± (1.68-2.81) and 96.00-104.20 ± (0.17-2.91), respectively. Instrumental detection limits ≤0.03 mg per 0.6 mL were obtained for the three drugs. Developed method has demonstrated high performance characteristics for analyzing investigated drugs and their admixtures. Student t-test at 95% confidence level revealed insignificant bias between the real and measured contents of investigated drugs in pure, pharmaceutical, urine and plasma samples and its admixtures. Application of the statistical F-test revealed insignificant differences in precisions between the developed method and arbitrary selected reference methods.

Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis.

OBJECTIVE: The present study was undertaken to investigate the pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. METHODS: Twenty patients received metronidazole (Flagyl ®, Pfizer, 235 East 42nd Street, NY, NY 10017) oral dose 500 mg twice a day for 3 consecutive days. Pharmacokinetic analyses of metronidazole were performed after a single oral dose on the morning of day 4. RESULTS: Although absolute estimates of metronidazole total body exposure were highest in women during early term pregnancy, weight-corrected estimates of exposure maximum plasma drug concentration (C(max)) and the area under the plasma concentration-versus-time curve (AUC(0-12)), along with apparent oral clearance and distribution volume, were not significantly different between women at early, middle, and late stages of pregnancy and were in the range of reported values for nonpregnant patients receiving a similar dose. CONCLUSIONS: The pharmacokinetic profile of metronidazole did not change at the different time points assessed during pregnancy.

Application of nuclear magnetic resonance spectroscopy for quantitative analysis of miconazole, metronidazole and sulfamethoxazole in pharmaceutical and urine samples.

Specific, accurate and precise NMR methods were developed for determining miconazole, metronidazole and sulfamethoxazole antibiotic drugs in authentic, pharmaceutical and urine samples. Proton nuclear magnetic resonance spectroscopy (1H NMR) with maleic acid as an internal standard and DMSO-d6 as NMR solvent were used. 1H NMR signals at 9.0, 8.06, 7.50 and 6.26 ppm corresponding to miconazole, metronidazole, sulfamethoxazole and maleic acid were respectively used for calculating the concentrations of drugs per unit dose. Average percent recoveries of (97.54-101.10), (98.06-100.46) and (97.83-102.83) with average uncertainties of 1.02, 0.45 and 0.86 were respectively obtained for determining authentic samples of miconazole, metronidazole and sulfamethoxazole in the concentration range of 0.92-170 mg/0.6 ml DMSO-d6. In pharmaceutical formulations and urine samples, average percent recoveries in the ranges of 97.50-101.33 and 94.46-100.86 were respectively obtained. Relative standard deviations (R.S.D.)

Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole.

A clinical study was undertaken in 12 healthy volunteers. At first, subjects received metronidazole (CAS 443-48-1; a substrate for cytochrome CYP3A4 and CYP2C9) alone at a dose of 400 mg every 8 h for 3 days. On day 4, blood and urine were collected at different time points and metronidazole levels were measured. After a washout period (> 10 half-lives) of one week silymarin (CAS 22888-70-6) was given at a daily dose of 140 mg for 9 days. From day 7 both silymarin (140 mg/day) and metronidazole (3 x 400 mg/day) were given till the 9th day. On day 10, blood and urine were collected as above and the levels of metronidazole and its metabolite were measured by HPLC. Administration of silymarin increased the clearence of metronidazole and its major metabolite, hydroxy-metronidazole (HM) by 29.51% and 31.90%, respectively, with a concomitant decrease in half-life, Cmax and AUC(0-48). Urinary excretions of acid-metronidazole (AM), HM as well as metronidazole in 48 h were decreased. The results indicate that silymarin might induce both intestinal P-glycoprotein and CYP3A4 upon multiple dose administration.

Diosmin pretreatment affects bioavailability of metronidazole.

OBJECTIVE: To screen for inhibitory effects of diosmin on cytochrome P(450)-mediated metabolism of metronidazole in healthy volunteers. DESIGN: Before/after non-blinded investigation conducted in healthy male volunteers. METHODS: After an overnight fast, metronidazole (two 400-mg tablets) was administered to 12 volunteers, either alone or after a 9-day pretreatment period with a once-daily dose of diosmin 500-mg tablets under direct observation. Serum concentrations of metronidazole up to 48 h postdose and urinary concentrations of metronidazole and its two major metabolites up to 24 h postdose were measured using reversed-phase high-performance liquid chromatography. RESULTS: Metronicazole plasma AUC((0- infinity )) and C(max) were significantly higher after diosmin pretreatment by (mean) 27% and 24%, respectively. However, time to reach peak concentration (t(max)) was not affected significantly. Urinary excretion of acid and hydroxy metabolites in urine was decreased significantly, while excretion of unchanged metronidazole was increased. CONCLUSION: Diosmin pretreatment significantly altered the metabolism of metronidazole, as demonstrated by changes in plasma pharmacokinetics as well as by urinary recovery of both parent drug and its major metabolites. This may be caused by the inhibition of cytochrome P(450) enzymes.

Determination of secnidazole in urine by adsorptive stripping voltammetry.

Cyclic voltammetry was used to explore the adsorption behavior of secnidazole on a hanging mercury drop electrode (HMDE). The effects of various operational parameters on the accumulation behavior of the adsorbed species were tested. Thus, a sensitive stripping voltammetry procedure for the determination of secnidazole with an adsorptive accumulation on the surface of HMDE has been developed. Measurements were taken by differential-pulse voltammetry after determination of the optimum conditions. The linear concentration range was 1 x 10(-8)-1 x 10(-7) s when using a 120 s preconcentration at -0.1 V vs. Ag/AgCl in acetate buffer of pH 4.0. The detection limit of secnidazole was 5 x 10(-9) M. The precision, expressed by the coefficient of variation, was 2.5% (n = 10) at a concentration of 1 x 10(-7) m. The method was successfully applied to the analysis of secnidazole in urine.

Quantitative assay of metronidazole by capillary zone electrophoresis with amperometric detection at a gold microelectrode.

Capillary zone electrophoresis was employed for the determination of metronidazole using end-column amperometric detection with a gold microelectrode at a constant potential of -0.52V vs. saturated calomel electrode. To overcome interference of oxygen in the solution, a deaeration injector and a deaeration protector at the detection cell were used. The optimum conditions of separation and detection are 1.0 x 10(-3) mol/L potassium dihydrogen citrate (KH2C6H5O7) for the buffer solution, 20 kV for the separation voltage, and 5 kV and 10 S for injection voltage and injection time, respectively. The limit of detection is 6.0 x 10(7) mol/L or 0.78 fmole (S/N = 3). The relative standard deviation is 3.9% for the electrophoretic peak current. The method was applied to the determination of metronidazole in human urine.

[The spectrophotometric determination of metronidazole and etimizol when jointly present in the urine]. / Spektrofotometricheskoe opredelenie metronidazola i étimizola pri sovmestnom prisutstvii v moche.

A method for spectrophotometric measurement of metronidasole and ethymisole jointly present in the urine has been developed. Combined polynomes have been designed to eliminate the effects of light-absorbing admixtures extracted from the urine on the results of analysis.

Non-induction of extrahepatic antipyrine and metronidazole metabolism evaluated from partially hepatectomized rats.

1. The effect of beta-naphthoflavone (BNF), given i.p. (n = 9) and orally (n = 9), on the metabolism of antipyrine and metronidazole was investigated in rats. 2. The clearances of antipyrine and metronidazole were determined on a single saliva sample. The rates of formation of antipyrine and metronidazole metabolites were determined from a 20 h urine sample and saliva clearance. 3. Administration of beta-naphthoflavone i.p. was significantly more effective than oral dosage on the induction of antipyrine and metronidazole metabolism (p < 0.05). 4. The capacity of extrahepatic tissues to metabolize antipyrine and metronidazole was quantitatively assessed in rats with and without pretreatment with beta-naphthoflavone immediately after sham operation or 70% partial hepatectomy (n = 40). 5. Antipyrine and metronidazole clearances correlated with liver weight in induced and non-induced rats. Linear regression of antipyrine and metronidazole clearances did show a non-significant Y-intercept (p > 0.05), indicating a negligible extrahepatic metabolism in both induced and in non-induced rats. 6. From a quantitative point of view this study indicates that induction of extrahepatic cytochrome P450 metabolism of antipyrine and metronidazole is negligible.